Medical Device News Magazine reports diagnostic imaging news. Keep up-to-date on new imaging developments.
The EVIS X1 endoscopy system received clearance earlier this year along with two compatible endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract.
As a world leader monitoring more than 600 million patients each year worldwide, Philips is creating an open patient monitoring ecosystem to bring together disparate medical devices and systems on a single interface. Interoperability between MDIP and PIC iX gives clinicians a new clinical perspective that enables the capture of streaming data flowing freely from a variety of medical device manufacturers on an open, scalable, secure platform. By disseminating this information through the Patient Information Center, clinicians have a single source, comprehensive overview of a patient’s condition that helps empower caregivers to make treatment recommendations confidently from anywhere throughout the hospital’s digital environment.
GlucoModicum is an innovative medtech company based in Finland, to design and eventually commercialize a proprietary non-invasive, wearable device that removes technology and patient-care roadblocks to continuous glucose monitoring (CGM).
In this demonstration, the project group will utilize iSurgery’s AI medical device, the medical image analysis software Chest Bone Indicator (3) (AI medical device), to assess bone health from chest radiographs and notify the results of health examinations for Fujitsu Group employees.
Dr. Richard Ljuhar, CEO and Co-Founder of ImageBiopsy Lab, explains, “Before even considering the use of AI, it’s crucial to grasp physicians’ diagnostic workflow and needs. For this purpose we’ve closely collaborated with leading MSK radiologists, orthopaedics, and traumatologists over the past years. We’re committed to revolutionizing the entire MSK diagnostic value chain for practitioners, patients, and healthcare systems.
“This first study to apply the Personal Performance in Mammographic Screening (PERFORMS) scheme to AI algorithms marks a remarkable achievement, showcasing our AI’s ability to match human performance in detecting breast cancer. It offers hope to patients worldwide and underscores AI’s potential to enhance cancer detection and treatment outcomes,” said Brandon Suh, CEO of Lunit.